In the event that a tumour type does not express EGFR for example liver cancer, which expresses asialoglycoprotein, then the bispecific antibody can be changed to anti‐asialoglycoprotein while the anti‐O‐polysaccharide component remains constant. This evidence concerns the gene EGFR and neoplasm.